anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:The titled pharmaceutical preparation obtained by adding interferon to a carrier consisting of a substance having decomposition properties in organism, capable of being embedded in organism, having low toxicity. CONSTITUTION:Interferon is added to a carrier (e.g., protein such as collagen, gelatin, albumin, etc., glucide such as chitin, etc, synthetic high polymer such as polyglycollic acid, polylactic acid, polyglutamic acid, etc.), to give pharmaceutical preparation of interferon. Preferably collagen or gelatin or a mixture of them is used with respect to safety and simplicity in use. In order to raise safety further, collagen is treated with an enzyme, telopeptide part is removed, to give atherocollagen having reduced antigen properties, which may be used. The dosage form of the pharmaceutical preparation is suspension injection, pellet, sphere, granule, powder, etc.
This study is a double-blind, randomized, placebo-controlled, dose-escalation study of DC-TAB in healthy human volunteers. DC-TAB is a solution of the small heat-shock protein alpha B-crystallin for intravenous injection, designed to induce selective immunological tolerance as a treatment for multiple sclerosis. In this first-in-man study, DC-TAB is administered to healthy subjects in varying doses and for a varying number of times, after which safety and tolerability is evaluated, as well as the impact of the treatment on antigen-specific responses by peripheral blood T cells and serum antibodies. Blood samples are additionally collected to measure serum concentrations of DC-TAB, and to determine the rate of clearance from the circulation. The study is double blind and placebo-controlled to strengthen the significance especially of immunological evaluations.

The study consists of two parts. In Part 1, subjects receive a single dose of DC-TAB or placebo whereas in Part 2, (different) subjects receive DC-TAB or placebo on 3 consecutive days. In Part 1, four groups of subjects (n=10) are studied in a single dose, dose-escalation design. Each group of subjects are randomized to receive either DC-TAB (n=8) or placebo (n=2) once. In Part 2, three groups of subjects (n=12) are studied in a multiple dose, dose-escalation design. Each group of subjects are randomized to receive either DC-TAB (n=9) or placebo (n=3) once daily on 3 consecutive days. The next higher dose group in each part of the study only starts once safety data up to 4 days for Part 1, up to 8 days for Part 2 of the previous dose group have been reviewed and have raised no safety concerns. Part 2 is started once all safety data of Part 1 have been reviewed. Immunological effects of the treatments are evaluated over a period of 28 days.
The aim of this study is to compare the effect of endurance and resistance exercises on endothelial function in patients with type 1 diabetes mellitus (T1DM). For this purpose, the sample size will consist of 15 patients with DM1, aged between 18 and 45 years, which will undertake the two types of exercises, randomly distributed. Ergospirometry testing will be performed in order to assess possible contraindications to the proposed protocol as well as functional capacity, which will be used in prescription of the endurance exercise session. Similarly, a strength maximal testing will be conducted and used in the prescription of the resistance exercise session.

The endothelial function will be evaluated by vascular reactivity of the forearm and circulating endothelial progenitor cells (EPC) counting. To analyze the vascular reactivity of the forearm, non-invasive venous occlusion plethysmography will be used, whereas flow cytometry method will be used to the analysis of the number of circulating EPC. The endurance exercise session will consist of 40 minutes of cycling on heart rate corresponding to 60% of VO2 max. The resistance exercise session will last 40 minutes, consisting of 4 sets of 12 repetitions at 60% of 1RM, in four exercises for lower limbs. The research will be performed at the Exercise Pathophysiology Research Laboratory of the Hospital de Clinicas de Porto Alegre. The investigators expect to find greater increase in the number of circulating EPC after the endurance exercise session, when compared to the benefits obtained from a session of resistance exercise. Likewise, it is expected to find greater benefits in relation to vascular reactivity of the forearm after a session of endurance exercise when compared to a session of resistance exercise. Considering that most part of the studies that analyze the effects of physical exercise on vascular function does not involve patients with DM1, this project aims to provide a clearer picture of the benefits of different exercises in the acute response of endothelial function in these patients.
OBJECTIVE: To evaluate associations between neurologic outcomes and early measurements of basal ganglia (BG) and thalamic (Th) perfusion using color Doppler ultrasonography (CDUS) in infants with hypoxic-ischemic encephalopathy (HIE).
STUDY DESIGN: Prospective study of infants with mild (n = 18), moderate (n = 17), and severe HIE (n = 14) and controls (n = 17). Infants with moderate-severe HIE received therapeutic hypothermia (TH). CDUS was performed at 24-36 hours and brain magnetic resonance imaging (MRI) at a median of 10 days. Development was followed through 2.5-5 years. The primary outcome was the association between BG and Th perfusion and brain MRI injury. Secondary analyses focused on associations between perfusion measurements and admission neurologic examinations, MRI scores in infants treated with TH, and motor and sensory disability, or death. An exploratory analysis assessed the accuracy of BG and Th perfusion to predict brain MRI injury in infants treated with TH.
RESULTS: Increased BG and Th perfusion on CDUS was observed in infants with severe MRI scores and those with significant motor and neurosensory disability or death through 2.5-5 years (P < .05). Infants with severe HIE showed increased BG and Th perfusion (P < .005) compared with infants with moderate HIE. No differences were identified between the between the control and mild HIE groups. Th perfusion ≥0.237 cm/second (Area under the curve of 0.824) correctly classified 80% of infants with severe MRI scores.
CONCLUSIONS: Early dynamic CDUS of the BG and Th is a potential biomarker of severe brain injury in infants with HIE and may be a useful adjunct to currently used assessments.
Participants will be enrolled in the study at the time of their first-trimester screen (10w3d-13w6d weeks of gestation) to the time of their delivery. Collection of first-trimester 3D-volume ultrasound imaging to measure the placental volume, blood flow, and vascularity and maternal serum markers will occur over a 6-12 months period. Collection of descriptive and pregnancy outcome information will be obtained from the electronic medical records will continue through their pregnancy episode (typical 9 months).
1,188,629. Steroid compositions. F. HOFFMANN-LA ROCHE & CO. A.G. 18 July, 1968 [28 July, 1967], No. 34358/68. Heading A5B. Therapeutic compositions for the treatment of disturbances of the normal hormonal equilibrium, for oral administration, comprise a medicament nucleus containing a sulpho-conjugated neutral steroid (wherein the steroid moiety is a C 21 , C 19  or C 18  steroid) coated with a layer which is resistant to gastric juice but which is capable of dissolution in the intestines. The steroid comprises the sulphates (acidic and mixed salts with ammonium, Na, K and Ca) and sulphatides (esters of acidic sulphates wherein the sulpho group is esterified with a non-toxic pharmaceutically acceptable monovalent or polyvalent alcohol e.g. glycerine, palmityl or stearyl alcohol) of non- phenolic steroids e.g. pregnenolone, desoxycorticosterone, progesterone, dehydro-epi-androsterone, testosterone and 19-nortestosterone. The coating may be composed of any conventional material e.g. keratin, shellac, colophony, cellulose acetate phthalate, cellulose acetate succinate, copolymers of styrene and maleic acid anhydride, copolymers of butyl partial ester of maleic acid with styrene and acrylic acid, copolymers of maleic acid anhydride and vinyl methyl ether and of styrene and methacrylic acid. The example relates to a dragee nucleus containing sodium dehydro-epi-androsterone sulphate coated with cellulose acetate phthalate.
Symptoms of depression, such as persistent sadness, problems sleeping, and inability to feel pleasure, interfere with the daily lives of more than 20 million Americans. Previous research indicates that telephone care management systems improve the quality and outcomes of depression care, but are too expensive to be used widely. Using secure messaging over e-mail would be more cost effective than telephone care. This study will examine whether a secure messaging care management program would be feasible, based on whether participants are willing to sign up for and continue with the program, and whether the program has a positive effect on those participants enrolled in the program.

Potential participants for this study will be contacted via e-mail, with a follow-up telephone call if they do not respond to the e-mail message. Only people who have used e-mails in the past year and who are starting antidepressant treatment will be contacted. The percentage of people contacted who enroll will be recorded.

Participation in this study will last 6 months. Participants will be randomly assigned to receive either a secure messaging care management program, based on effective telephone management programs, or their usual care with no intervention. Those receiving the secure messaging program will receive an initial welcome message and monitoring messages approximately 2, 6, and 10 weeks after treatment has begun. The monitoring messages will include structured assessments of depression severity, medication adherence, medication side effects, and barriers to continuing treatment. Participants who do not respond to monitoring messages will receive up to two e-mailed reminders. Care managers will analyze the results of monitoring messages, provide feedback and recommendations to physicians, coordinate physician follow-ups, and facilitate emergency care or specialty referrals. Care managers will also provide patients with motivation, based on semi-scripted protocols, and education concerning their disorder and treatment. Measures of the success of the study will be taken at enrollment and after 6 months of participation. Specific measurements will include the response rate of recruitment e-mails, response rate for follow-up data collection, proportion of those in the secure messaging program who complete the monitoring assessments, effects of the program on antidepressant treatment, and effects of the program on patient satisfaction.
The present invention refers to a kalanchoe flammea extract with ethyl acetate (KfAcOEt-COP), the fractions and major compounds thereof, which may be used as cytotoxic or apoptosis inducers against prostate cancer, considering that Docetaxol is a more efficient drug, the KfAcOEt-COP extract (which has fractions and major compounds) shown to have more advantages than Docetaxol. First, a phyto-chemical study was performed where alkaloids, sterols and cardiac glycosides were found. Referring to cytotoxicity, the KfAcOEt-COP effect was evaluated as well as its fractions over the viability of PC3, LNCaP, PrEC and lymphocytes; these may exert a doses response effect after 24 h of exposition. Genotoxic studies in vitro and in vivo of KfAcOEt-COP and its fractions were performed, where no toxicity was found. The KfAcOEt-COP extract has evidence of inducing apoptosis after 6 h, the PC3 exposed to the extract showing an overproduction of ROS. The activation of caspases is intrinsically measure d, inducing the fragmentation of the DNA, showing a high level of excision of PARP-1 and inducing cell arrest in the synthesis phase. In an animal model, KfAcOEt-COP is able to inhibit the tumor growth in CaP cells.
PURPOSE: To obtain a medicine preparation containing a heterocyclic group compound, showing excellent antitumor activity, effective for treating intractable tumor and for preventing distant metastasis to another organ, etc. CONSTITUTION: This medicine composition comprises a compound of the formula (R<1> and R<3> are each a halogen, H bondable through a hetero atom or a hydrocarbon residue; R<2> is a hydrocarbon residue; X is O or S; Z is a bifunctional group; Ar is an aromatic group) or its salt as an active ingredient. The compound of the formula has antitumor action on primal cancers of solid cancers such as prostatic cancer, pancreatic cancer, lung cancer, etc., controlling action on metastasis, preventing effect on relapse after surgical operation and improving action on symptoms such as pains followed by cancers, cachexia, etc. The compound of the formula has bacteria eliminating effect on Helicobacter pylori and is useful for preventing and treating diseases caused by the bacterium.  The compound is pharmaceutically manufactured into an oral administration agent, solution, drop, injection, agent for external use (e.g. nasal medicine and percutaneous medicine), suppository, etc. A dose, for example, is 0.1-20mg/kg calculated as the compound of the formula in one administration and daily administered once to several times dividedly in the case of oral administration to a patient of prostatic cancer.
Following discharge, patients will return to the internal medicine (IM) outpatient clinics at 2-4 weeks, 3, and 6 months for consultation. These scheduled consultations will comprise of history taking, recording of any new events, physical examination and recommendations as clinically indicated.
From Alzheimer's disease to amyotrophic lateral sclerosis, the molecular cascades underlying neurodegenerative disorders remain poorly understood. The clinical view of neurodegeneration is confounded by symptomatic heterogeneity and mixed pathology in almost every patient. While the underlying physiological alterations originate, proliferate, and propagate potentially decades before symptomatic onset, the complexity and inaccessibility of the living brain limit direct observation over a patient's lifespan. Consequently, there is a critical need for robust computational methods to support the search for causal mechanisms of neurodegeneration by distinguishing pathogenic processes from consequential alterations, and inter-individual variability from intra-individual progression. Recently, promising advances have been made by data-driven spatiotemporal modeling of the brain, based on in vivo neuroimaging and biospecimen markers. These methods include disease progression models comparing the temporal evolution of various biomarkers, causal models linking interacting biological processes, network propagation models reproducing the spatial spreading of pathology, and biophysical models spanning cellular- to network-scale phenomena. In this review, we discuss various computational approaches for integrating cross-sectional, longitudinal, and multi-modal data, primarily from large observational neuroimaging studies, to understand (i) the temporal ordering of physiological alterations, i(i) their spatial relationships to the brain's molecular and cellular architecture, (iii) mechanistic interactions between biological processes, and (iv) the macroscopic effects of microscopic factors. We consider the extents to which computational models can evaluate mechanistic hypotheses, explore applications such as improving treatment selection, and discuss how model-informed insights can lay the groundwork for a pathobiological redefinition of neurodegenerative disorders.
Medicinal preparations which are efficaious against bacterial toxins are prepared from liver or spleen by subjecting the tissue to autolysis without addition of acid and then extracting the autolysate with water, or a water-soluble organic solvent, with the addition of a little acid and at a low temperature, and treating the solution with an agent to eliminate ballast substances, particularly proteins. The clear liquid obtained may be dried, and the residue extracted with concentrated methyl alcohol to yield a solution which is dried. Pure or aqueous methyl alcohol may be used as the extracting agent for the autolysate, and iron dialysate or lead acetate may be used to eliminate ballast substances.  The Specification as open to inspection under Sect. 91 refers also to extraction of the liver or spleen of normal animals for a prolonged time at low temperature at a pH between 4 and 6 without previous autolysis, and to simple extraction at a feebly acid reaction of the organs of immunized animals; it states also that organic solvents without addition of acid may be used for the extraction and that the extracts so obtained are poor in ballast substances such as albumin and electrolytes.  An example relating to the extraction of the spleen of an immunized animal with N/100 hydrochloric acid, followed by purification by means of iron dialysate is included.  This subject-matter does not appear in the Specification as accepted.
<P>PROBLEM TO BE SOLVED: To provide a method for manufacturing a porous body for medical treatment made of a polymer without using a freeze dryer.  <P>SOLUTION: A polymer solution is prepared by dissolving the polymer to become a material of the porous body for medical treatment in a solvent. This polymer solution is poured into a mold of a desired shape and is frozen in a freezer to obtain a frozen body of the polymer solution. Afterward, the solvent is extracted from the frozen body by using an extraction solvent which is hard to dissolve or can not dissolve in the polymer contained in the frozen body and can dissolve in the solvent. Finally, drying is performed for removing the solvent for extraction contained in the porous body.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The mode of action of allergenic extracts is still under investigation. The pharmacological action of allergenic extracts used diagnostically is based on the liberation of histamine and other substances when the allergen reacts with IgE antibodies attached to the mast cells.(11) The pharmacological action of allergenic extracts used for immunotherapy is based on an increase of IgG antibodies and allergen-specific T lymphocyte cells. 

a. Prick-puncture tests on Cat allergic subjects: 11 puncture tests (bifurcated needle) on cat allergic subjects yielded the following:

b. Patients tested only by the intradermal method:

Intradermal tests (using 0.05mL) on 11 puncture positive patients BAU/mL to elicit 50mm sum of dia. of erythema reaction
Methods and compositions for inducing penile erections, sufficient for vaginal penetration, in a human male suffering from impotence are provided. Kits containing the compositions in containers for single dosage administration are provided. Compositions for treating impotence that is of psychogenic or neurogenic origin contain a neuropeptide selected from the group consisting vasoactive intestinal peptide (VIP) and peptide N-terminal histidine C-terminal methionineamide (PHM) and are formulated in a pharmaceutically acceptable carrier that has a pH of about 2 to about 4.5, preferably between about 2 and about 3.5, and most preferably about 3. Compositions for treating impotence of almost origin, including severe atherosclerosis, contain (1) a neuropeptide selected from the group consisting of vasoactive intestinal peptide and peptide N-terminal histidine C-terminal methionineamide and (2) an alphaadrenergic blocker, such as phentolamine or prazosin. Ethylenediaminetetraacetic acid (EDTA) can be, and preferably is, included in the formulations to provide stable, physiologically acceptable compositions. Such EDTA-containing compositions are especially suitable for use in kits since, under proper storage conditions, they are stable for prolonged period of time. In practising the method, the composition is administered by intracavernosal injection accompanied by or followed by sexual stimulation.
Participants will receive one capsule of the test formulation containing Duloxetine 60 mg. The capsules will be taken with water and in a fasting condition.
Participants in this arm will start LSMT at baseline and have a weight loss response assessment at T=24 weeks: if body mass index (BMI) is down 5% at T=24 weeks, the participant will continue with LSMT for the remainder of the study (i.e. for another 24 weeks); if BMI is not down 5% at T=24 weeks, the participant will add phentermine to LSMT (phentermine+LSMT) and undergo a second weight loss response assessment after 12 weeks of phentermine+LSMT; i.e. at T=36 weeks. At T=36 weeks, if BMI is down 5% with phentermine+LSMT, the participant will continue with phentermine+LSMT for the the remainder of study (i.e. for another 12 weeks); if BMI is not down by 5% at T=36 weeks, the participant will be randomized to topiramate+phentermine+LSMT or topiramate+placebo+LSMT for the remainder of the study (i.e. for another 12 weeks).
An extended use self-contained, wearable medical device is provided. The device may be configured with an infusion needle deployment mechanism to variably insert and retract an infusion needle to different depths, or to completely retract the infusion needle from the infusion site and then re-insert the needle after a predetermined period of time, during an infusion cycle in order to extend the viability of the infusion site. The device may also comprise dual needle deployment mechanisms that variably insert and retract the infusion needles. A flow sensor may be provided to detect the stoppage of flow through the infusion cannula and signal the needle deployment mechanism to attempt infusion at a different depth or to deploy a second infusion needle. A re-fillable reservoir assembly may be provided to supply a drug over the extended use of the device. The device may also be partially reusable or partially-disposable.
PE (plus homework) + Cognitive Restructuring (CR) (plus homework) + CR (plus homework) + EX (plus homework) + EX: 20 participants will receive two cognitive restructuring group sessions after the psycho-education session. In these two session they will practice identifying dysfunctional cognitions and formulating more functional (alternative/helping) cognitions. After the cognitive sessions they will receive two exposure group sessions. In these two sessions they will move up in their fear hierarchy by practicing public speaking/performance tasks.
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory disease that generates multiple cytokines. Here, we present an example of the cytokines forming a cytokine storm and its effects on the patient.
CASE PRESENTATION: We report the case of a 55-year-old man who had severe but stable HS. Serum samples were collected from the patient and extraordinarily elevated cytokine concentrations were identified in the patient's serum.  Conclusion: Cytokine storms may be a condition associated with HS posing additional risk to patient survival. J Drugs Dermatol. 2024;23(5):e134-e136.     doi:10.36849/JDD.7860R1e.